ADAPY
Adaptimmune Therapeutics PLCCompany with tickers: ADAPY
CIK
1621227
Shares Outstanding
1,590,309,546
Website
https://www.adaptimmune.com
Investor Relations
https://www.adaptimmune.com/investors-and-media
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $18 | USD | 2025-07-27 | 10-Q | 2025-08-13 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | — | ||||
| Operating Income | — | ||||
| Net Income | — | ||||
| EPS (Basic) | — | ||||
| EPS (Diluted) | — |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Single Reportable Segment | $27,148,000 | $60,281,000 | $178,032,000 |
By Product & Service (USD)
| Component | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Development Revenue | — | $1,122,000 | $3,958,000 | $6,149,000 | $27,148,000 | $60,281,000 | $176,796,000 |
| Product | — | — | — | — | — | — | $1,236,000 |
| Development And Service | $20,391,000 | — | — | — | — | — | — |
| License Revenue | $39,114,000 | — | — | — | — | — | — |